Related Experiment Videos
Towards patient-specific tumor antigen selection for vaccination
Hans-Georg Rammensee1, Toni Weinschenk, Cécile Gouttefangeas
1Department of Immunology, Institute for Cell Biology, University of Tübingen, Tübingen, Germany. rammensee@uni-tuebingen.de
Immunological Reviews
|November 26, 2002
Summary
This review explores personalized cancer vaccines by analyzing tumor antigens for targeted immunotherapy. Identifying key antigens could improve patient treatment outcomes through custom vaccine design and administration.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Cancer immunotherapy aims to harness the immune system to fight tumors.
- Personalized medicine approaches are increasingly important in cancer treatment.
- Identifying specific tumor antigens is crucial for developing targeted therapies.
Purpose of the Study:
- To review the potential of combining molecular antigen analysis with tailored vaccine design for individual cancer patients.
- To explore the technical and logistical challenges in developing patient-specific therapeutic immunization strategies.
Main Methods:
- Differential gene expression analysis between tumor and normal tissues.
- Analysis of human leukocyte antigen (HLA) ligands on tumor cells.
- Data mining to identify suitable antigens for adaptive immune system attack.
- On-demand clinical-grade production of vaccine components (e.g., peptides).
- Vaccination and patient monitoring protocols.
Main Results:
- The identified antigens, though not exhaustive, may be sufficient for enhanced immunotherapy.
- The process involves a multi-step approach from molecular analysis to clinical application.
Conclusions:
- Combining molecular profiling of tumor antigens with custom vaccine design offers a promising avenue for cancer immunotherapy.
- Significant technical and logistical hurdles must be overcome for successful implementation of patient-tailored therapeutic immunization.